Neumora Therapeutics (NMRA) Competitors $0.68 -0.04 (-5.31%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.68 +0.00 (+0.49%) As of 05/23/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. MAZE, SIGA, ZVRA, SAGE, AMLX, PRTA, PRTC, ABVX, TRML, and PGENShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Maze Therapeutics (MAZE), SIGA Technologies (SIGA), Zevra Therapeutics (ZVRA), Sage Therapeutics (SAGE), Amylyx Pharmaceuticals (AMLX), Prothena (PRTA), PureTech Health (PRTC), ABIVAX Société Anonyme (ABVX), Tourmaline Bio (TRML), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Maze Therapeutics SIGA Technologies Zevra Therapeutics Sage Therapeutics Amylyx Pharmaceuticals Prothena PureTech Health ABIVAX Société Anonyme Tourmaline Bio Precigen Maze Therapeutics (NASDAQ:MAZE) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership. Which has preferable earnings & valuation, MAZE or NMRA? Maze Therapeutics has higher revenue and earnings than Neumora Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaze Therapeutics$167.50M2.69N/AN/AN/ANeumora TherapeuticsN/AN/A-$235.93M-$1.61-0.42 Does the media prefer MAZE or NMRA? In the previous week, Neumora Therapeutics had 7 more articles in the media than Maze Therapeutics. MarketBeat recorded 8 mentions for Neumora Therapeutics and 1 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 0.73 beat Neumora Therapeutics' score of 0.59 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in MAZE or NMRA? 47.7% of Neumora Therapeutics shares are owned by institutional investors. 26.8% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is MAZE or NMRA more profitable? Maze Therapeutics' return on equity of 0.00% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Maze TherapeuticsN/A N/A N/A Neumora Therapeutics N/A -73.63%-68.97% Do analysts rate MAZE or NMRA? Maze Therapeutics currently has a consensus price target of $25.67, indicating a potential upside of 149.68%. Neumora Therapeutics has a consensus price target of $9.29, indicating a potential upside of 1,266.15%. Given Neumora Therapeutics' higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22 Does the MarketBeat Community believe in MAZE or NMRA? Neumora Therapeutics received 24 more outperform votes than Maze Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Maze Therapeutics an outperform vote while only 75.00% of users gave Neumora Therapeutics an outperform vote. CompanyUnderperformOutperformMaze TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesNeumora TherapeuticsOutperform Votes3075.00% Underperform Votes1025.00% SummaryMaze Therapeutics beats Neumora Therapeutics on 7 of the 12 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$109.94M$2.92B$5.33B$8.31BDividend YieldN/A1.63%5.20%4.10%P/E Ratio-0.3631.0126.7219.60Price / SalesN/A395.77395.56117.96Price / CashN/A168.6838.3234.62Price / Book0.223.236.764.50Net Income-$235.93M-$72.35M$3.23B$248.40M7 Day Performance-2.90%1.81%0.37%-1.03%1 Month Performance-9.31%-0.05%7.04%7.94%1 Year Performance-92.59%-24.97%18.61%8.50% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics2.8668 of 5 stars$0.68-5.3%$9.29+1,266.1%-92.7%$109.94MN/A-0.36108Gap DownMAZEMaze TherapeuticsN/A$10.13+5.3%$25.67+153.4%N/A$443.65M$167.50M0.00121SIGASIGA Technologies1.3744 of 5 stars$5.94+4.9%N/A-20.7%$424.36M$138.72M4.9540ZVRAZevra Therapeutics3.3907 of 5 stars$7.75-1.5%$22.29+187.6%+92.7%$423.76M$23.61M-3.9320Analyst UpgradeSAGESage Therapeutics3.8353 of 5 stars$6.75+2.9%$8.81+30.6%-42.3%$422.69M$47.40M-1.02690AMLXAmylyx Pharmaceuticals3.2945 of 5 stars$4.60-0.2%$9.67+110.1%+198.3%$409.79M$-1,272,000.00-1.20200PRTAProthena3.8075 of 5 stars$7.61+2.4%$51.71+579.6%-67.3%$409.62M$137.94M-3.31130High Trading VolumePRTCPureTech Health2.1317 of 5 stars$17.03+1.5%$45.00+164.3%-37.8%$408.92M$4.32M0.00100Positive NewsGap DownABVXABIVAX Société Anonyme2.4741 of 5 stars$6.40-4.6%$34.00+431.3%-59.2%$405.88MN/A0.0061Positive NewsGap DownTRMLTourmaline Bio1.8516 of 5 stars$15.78+4.5%$49.33+212.6%+12.2%$405.31MN/A-5.6044PGENPrecigen3.3726 of 5 stars$1.37+3.0%$7.00+410.9%+2.2%$404.38M$3.93M-2.49190High Trading Volume Related Companies and Tools Related Companies Maze Therapeutics Competitors SIGA Technologies Competitors Zevra Therapeutics Competitors Sage Therapeutics Competitors Amylyx Pharmaceuticals Competitors Prothena Competitors PureTech Health Competitors ABIVAX Société Anonyme Competitors Tourmaline Bio Competitors Precigen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMarket chaos is the new normalIt happened again. Wall Street swung like a wrecking ball after Trump paused tariffs on smartphones, lapto...Augusta Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NMRA Stock Free NMRA Stock Alerts